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Abstract
B-Catenin, the chief oncogenic component of the ca-
nonical Wnt pathway, is known to be involved in a
variety of cancers, including hepatocellular carcinoma
(HCC). Although the mechanism of B-catenin activation
in HCC is multifactorial, it is indisputably implicated
at various stages of hepatocarcinogenesis, making it
an attractive therapeutic target. Here we investigate
the effect of small interfering RNA–mediated B-catenin
knockdown on the growth and survival of human hepa-
toma cell lines with (HepG2) and without (Hep3B)
B-catenin mutations. Transfection of HepG2 and Hep3B
cells with human B-catenin (CTNNB1) small interfer-
ing RNA resulted in a significant B-catenin decrease,
as confirmed by Western blot analyses and immuno-
fluorescence, also leading to decreased expression of
known target genes such as cyclin D1 and glutamine
synthetase. The decrease in B-catenin activity was con-
firmed by TOPflash reporter luciferase assay. The func-
tional impact of diminished B-catenin was exhibited as
temporal decrease in tumor cell viability by the MTT
assay. A concomitant decrease in tumor cell prolifera-
tion was also evident with [3H]thymidine incorporation
and verified with soft agar assays. Thus, B-catenin is
essential for the survival and growth of hepatoma cells
independent of mutations in the B-catenin gene and
provide a proof of principle for the significance of the
therapeutic inhibition of B-catenin in HCC.
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Introduction
The Wnt/b-catenin pathway is important for normal growth
and development [1]. However, anomalous activation of Wnt
signaling in adults is often associated with oncogenesis [2–
4]. Aberrant signaling involving the stabilization and nuclear
translocation of b-catenin has been observed in cancers of
the colon, rectum, lung, shin, breast, liver, and pancreas [5–
12]. Interestingly, the activation of Wnt signaling can occur
due to multiple mechanisms and can result from dysregula-
tion of upstream effectors and mutations in downstream
components [13].
Hepatocellular carcinoma (HCC), which is the major primary
malignant tumor of the liver, is a disease with poor prognosis
due to lack of effective treatment, making it essential to identify
novel therapeutic targets [14]. Aberrant activation of b-catenin
has been identified in a significant subset of HCC patients with
molecular bases ranging from mutations in the -catenin gene
(CTNNB1) (26–34%) or AXIN1/2 (5%) to upregulation of the
frizzled-7 receptor (90%) [15–17]. Although additional known
or unknown mechanisms might also contribute to b-catenin
stabilization in HCC, its role in various stages of hepatocarcino-
genesis ranging from hepatic adenoma to hepatoma is indis-
putable [18].
Based on the role of b-catenin in cellular events common to
the processes of development and oncogenesis such as prolif-
eration and survival, we initiated the current study [19–21]. We
used small interfering RNA (siRNA) directed against b-catenin
to examine the impact of successful b-catenin knockdown on
two human HCC cell lines and to demonstrate an indispensable
role of b-catenin in tumor cell survival and proliferation.
Materials and Methods
Cell Culture, Treatment, and Transient Transfection
Human HCC cell lines HepG2 and Hep3B were obtained
from the American Type Culture Collection (Manassas, VA).
Cells were plated in six-well plates and cultured in Eagle’s
minimal essentialmedium (EMEM) supplementedwith 10%vol/
vol fetal calf serum at 37jC in a humidified 5% carbon dioxide
atmosphere. The cells were grown to 50% to 60% confluence,
followed by serum starvation for 16 hours. For siRNA inhibi-
tion studies, the cells were transfected with validated human
b-catenin (CTNNB1) siRNA or negative control siRNA 1 (Ambion,
Inc., Austin, TX) at a final concentration of 100 nM in the pres-
ence of an Oligofectamine reagent (Invitrogen, Carlsbad, CA), as
per the manufacturer’s instructions. After transfection, the cells
Address all correspondence to: Satdarshan P. S. Monga, MD, UPCI-GI Oncology/MIRM-Liver,
University of Pittsburgh School of Medicine, 200 Lothrop Street, S-421 BST, Pittsburgh, PA
15216. E-mail: smonga@pitt.edu
1This report was funded, in part, by the American Cancer Society (grant RSG-03-141-01-CNE
to S.P.S.M.) and the National Institutes of Health (grants 1RO1DK62277 and 1R01CA124414
to S.P.S.M.) Rango’s Fund for Enhancement of Pathology Research.
Received 11 June 2007; Revised 1 September 2007; Accepted 7 September 2007.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.07469
Neoplasia . Vol. 9, No. 11, November 2007, pp. 951–959 951
www.neoplasia.com
RESEARCH ARTICLE
were harvested at 24, 48, and 72 hours for protein extraction
and additional analysis. All experiments were performed in
triplicate, and representative results are reported.
Protein Extraction and Western Blot Analysis
Protein extraction from cell lines and Western blot anal-
ysis were performed as previously described [5,22,23].
Briefly, the HCC cell lines from siRNA treatment were used
for total cell lysate preparation. Homogenization was per-
formed in 200 ml of RIPA buffer containing fresh protease and
phosphatase inhibitors (Sigma, St. Louis, MO). The concen-
tration of the protein in lysates was determined by bicincho-
ninic acid protein assay, with bovine serum albumin as
standard. Aliquots of samples were stored at 80jC until
use. Twenty or 50 mg of proteins was resolved by SDS-
PAGE analysis using the mini-PROTEIN 3-electrophoresis
module assembly (Bio-Rad, Hercules, CA) and transferred
to Immobilon PVDF membranes (Bio-Rad). The primary
antibodies used were against b-catenin, cyclin D1, glu-
tamine synthetase (GS; Santa Cruz Biotechnology, Santa
Cruz, CA), and b-actin (Chemicon, Temecula, CA). Horse-
radish peroxidase–conjugated secondary antibodies were
purchased from Chemicon. The proteins were detected by
Super-SignalWest Pico Chemiluminescent Substrate (Pierce,
Rockford, IL) and visualized by autoradiography. Densitomet-
ric analysis on blots was performed by the NIH Imager soft-
ware (NIH, Bethesda, MD), and the average integrated optical
density in the b-catenin siRNA–treated group was normalized
to control siRNA-treated group at the corresponding times.
The differences were assessed for statistical significance with
Student’s t test, and P < .05 was considered significant.
Immunofluorescence Microscopy
Cells were grown to 50% confluence on glass cover slips
in 24-well plates. After b-catenin siRNA transfection for
48 hours, the cover slips were washed once with phosphate-
buffered saline (PBS) and fixed in 100% methanol for 3 min-
utes at 20jC. Staining was performed as described else-
where [24]. The secondary antibody was Cy3, which was
conjugated and obtained from Jackson Immunoresearch
(West Grove, PA). Nuclei were counterstained with 40,6-
diamidino-2-phenylindole. The cover slips were then placed
on slides with a drop of gelvatol and viewed on a Nikon
Eclipse epifluorescence microscope (Nikon), and images
were obtained with a Sony CCD camera (Sony).
-Catenin/Tcf Transcription Reporter Assay
b-Catenin/Tcf transcriptional reporter activity was per-
formed as previously described [23]. Briefly, after b-catenin
siRNA transfection for 24 hours, the cells were transiently
transfected with the reporter construct TOPflash or FOPflash
(Upstate, Lake Placid, NY). TOPflash has three copies of the
Tcf/Lef sites upstream of a thymidine kinase (TK) promoter
and the firefly luciferase gene. FOPflash has mutated copies
of Tcf/Lef sites and is used as a control for measuring
nonspecific activation of the reporter. All transfections were
performed using 1.8 mg of TOPflash or FOPflash plasmids
and FuGene HD reagent (Roche, Indianapolis, IN). To nor-
malize transfection efficiency in reporter assays, the cells
were cotransfected with 0.2 mg of internal control reporter
Renilla reniformis luciferase driven under the TK promoter
(pRL-TK; Promega, Madison, WI). Twenty hours after TOP-
flash or FOPflash transfection, luciferase assay was per-
formed, using the Dual Luciferase Assay System kit, in
accordance with the manufacturer’s protocols (Promega).
Relative luciferase activity (in arbitrary units) was reported as
fold induction after normalization for transfection efficiency.
The normalized luciferase activity from experiments per-
formed in triplicate was compared between the experimental
and control groups for statistical significance with unpaired
Student’s t test. P < .01 was considered significant.
Cell Viability Assay
Cell viability assay was performed as previously de-
scribed [23]. All experiments were performed in triplicate.
Briefly, at 24, 48, and 72 hours after b-catenin siRNA
transfection, 10% vol/vol of 5 mg/ml 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) diluted
in PBS was added to HepG2 and Hep3B cultures. After
30 minutes of incubation, the medium was aspirated and
washed with PBS. Isopropanol (600 ml) was added and
shaken gently for 5 minutes. Two hundred microliters of this
solution was transferred to a 96-well plate, and absorbance
was measured at 570 nM. The mean (±SEM) absorbance
units obtained from three experiments for each group were
compared for statistical significance with Student’s t test, and
P < .01 was considered highly significant. The data were
normalized to their respective controls and are presented as
a bar graph.
Cell Proliferation Assay
[3H]Thymidine incorporation analyses were performed as
previously described [23]. Briefly, 4 hours after b-catenin or
control siRNA transfection in Hep3B and HepG2 cells,
[3H]thymidine (2.5 mCi/ml) was added to culture media.
These cells were cultured for [3H]thymidine incorporation
for an additional 24, 48, or 72 hours. Alternatively, an
additional set of HepG2 cells was transfected with siRNA
against b-catenin a second time, at 24 hours after the initial
transfection. This was followed 4 hours later by the addition
of [3H]thymidine (2.5 mCi/ml), and the cells were cultured
for 24 or 48 hours. Next, the cells were washed with 0.9%
NaCl and lysed in 0.2% SDS, 1 SSC (150 mM NaCl and
15 mM Na–citrate, pH 7.0), and 5 mM EDTA, and aliquots
were used to determine [3H]thymidine incorporation on a
Beckman Scintillation counter (Beckman), and total DNA
using Hoechst dye H33258 and a fluorescence meter (DyNA
Quant 200; Hoefer). Counts from the experiments performed
in triplicate from each group were compared for statistical
significance with Student’s t test. P < .01 was considered
highly significant, and P < .05 was considered significant.
The analysis from sequential (2) siRNA-treated cells was
normalized to their respective controls and is presented as a
bar graph.
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Soft Agar Assay
A 1.5-ml layer of 0.5% agar (wt/vol) in EMEM with 10%
FBS was poured in 35-mm Petri dishes. HepG2 and Hep3B
cells were treated with control or b-catenin siRNA for 24 hours
at 100 nM in the presence of Oligofectamine reagent (Invi-
trogen) and resuspended in 0.35% agar (wt/vol) in EMEMwith
5% FBS at a density of 5000 cells/1.5 ml. Cell suspensions
(1.5 ml) were poured on the top of the base layer, allowed to
solidify, and incubated at 37jC in the presence of 5% CO2 for
14 days (HepG2 cells) and 21 days (Hep3B cells). The
colonies were stained with 0.005% crystal violet for 1 hour.
Colonies containing > 10 cells were counted under an Olym-
pus microscope (Olympus). Absolute counts were compared
for statistical significance with Student’s t test and are pre-
sented as a bar graph.
Results
siRNA Inhibits -Catenin Expression in HCC Cell Lines
The human hepatoma cell lines Hep3B and HepG2 were
grown to around 50% confluence, followed by transfection
with either human b-catenin (CTNNB1) or control siRNA
(referred to as control), as indicated in the Materials and
Methods section. Protein lysates obtained from the tumor
cells at different time points after CTNNB1 siRNA transfec-
tion showed a temporal decrease in total b-catenin protein
in both HepG2 and Hep3B cells compared to controls (Fig-
ure 1A). HepG2 cells harbor two species of b-catenin: wild-
type or the 96-kDa form, and a more prominent truncated
or stable 75-kDa form (tb-catenin) due to partial exon 3 de-
letion that contains phoshorylation sites critical for eventual
degradation of b-catenin. siRNA transfection led to a de-
crease in both species of b-catenin in HepG2 cells, albeit the
wild-type form showed an immediate and robust knockdown
compared to tb-catenin. Although control siRNA-transfected
HepG2 cells showed a time-dependent increase in tb-catenin
protein levels, b-catenin siRNA–treated cells failed to show
this increase, thus suggesting that de novo synthesis of
b-catenin might also contribute to the truncated species of
b-catenin. Densitometric analysis of Western immunoblots
identified a dramatic and highly significant (P < .01) decrease
in the full-length b-catenin protein in both HepG2 and Hep3B
cells within 24 hours, although a more prominent effect was
evident after 48 hours (Figure 1, B and C). In addition, a
modest but significant (P < .01) decrease in tb-catenin in
HepG2 cells was observed after 48 hours, with a more dra-
matic difference at 72 hours after a single transfection of
CTNNB1 siRNA (Figure 1B).
siRNA Inhibits -Catenin Activation as Observed
by a Downregulation of Known Target Genes
Cyclin D1 and GS
Next, to confirm whether the decrease in total b-catenin
protein in both HepG2 and Hep3B cells following siRNA
treatment also affected the transcriptional regulatory func-
tion of b-catenin, the protein lysates were examined for
the protein expression of two known targets: cyclin D1 and
GS. Although the former is regulated by additional factors
as well, GS is a more selective Wnt/b-catenin target in the
liver [21]. After CTNNB1 siRNA transfection, a decrease in
cyclin D1 and GS was detectable in both cell lines, support-
ing a functional decrease in the b-catenin protein in both
cell lines (Figure 1A). This decrease was more dramatic in
Hep3B cells than in HepG2 cells, although it was significant
in both cells following b-catenin siRNA transfections (Figure 1,
D and E ).
Decrease in -Catenin and Its Nuclear Localization
Are Also Detectable By Immunofluorescence in Hep3B
and HepG2 Cells after siRNA Transfection
To confirm a decrease in total b-catenin, as well as any
changes in its localization following CTNNB1 or control siRNA
transfection, Hep3B and HepG2 cells were examined for
b-catenin with immunofluorescence, as discussed in the Ma-
terials andMethods section. AlthoughHep3B cells transfected
with control siRNA for 48 hours showed membranous and
nuclear localization, a vivid decrease in b-catenin was evident
in CTNNB1 siRNA–transfected cultures at the same time,
which displayed occasional cells with membranous or, even
rarely, nuclear b-catenin (Figure 2, A and B). In addition,
although control HepG2 cells showed extensive membranous
and nuclear b-catenin, the CTNNB1 siRNA–transfected cells
showed a similar and pronounced b-catenin decrease at
48 hours as well (Figure 2, C and D).
-Catenin/Tcf Reporter Assay Confirms siRNA-Mediated
Loss of -Catenin Activity in Hep3B and HepG2 Cells
Next, we examined the effect of b-catenin knockdown on
its activity with the TOPflash reporter assay, which is a direct
and reliable measure of the b-catenin/Tcf–dependent tran-
scriptional activity. TOPflash and FOPflash activities were
measured following b-catenin siRNA transfection for 48 hours,
as described in the Materials and Methods section. A signif-
icant downregulation in TOPflash reporter activity, without any
effect on FOPflash activity, was apparent after CTNNB1
siRNA transfection in Hep3B and HepG2 tumor cells com-
pared to control siRNA–transfected cells (Figure 3). The ac-
tivity was decreased around threefold to fivefold in HepG2
cells, and by fivefold to eightfold in Hep3B cells, clearly
identifying a pronounced loss of b-catenin function in both
tumor cells.
Effect of -Catenin Knockdown on the Survival
of Hepatoma Cells
To address any biologic relevance of the loss of b-catenin
function, we investigated the impact of b-catenin siRNA on
the survival of Hep3B and HepG2 cells. CTNNB1 siRNA–
transfected tumor cells were examined for viability by MTT
assay, as described in the Materials and Methods section.
Although a consistently small but insignificant effect on the
survival of HepG2 cells was apparent after 24 hours of
transfection, a more robust (f 35%) and significant (P <
.01) decrease was observed at 48 and 72 hours (Figure 4A).
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A significant decrease in Hep3B cell viability was observed
as early as 24 hours after CTNNB1 siRNA transfection
(P < .01), which was further augmented to around a 40%
decrease in viability by 48 to 72 hours (Figure 4B). These
results demonstrate an important role in tumor cell viability.
Effect of -Catenin siRNA on the Proliferation of HCC Cells
Next, we examined the effect of b-catenin loss on tumor
cell proliferation. Thymidine incorporation was employed as
a measure of DNA synthesis after CTNNB1 or control siRNA
transfection, as described in the Materials and Methods
section. A significant decrease in thymidine incorporation in
b-catenin siRNA–transfected HepG2 cells (P < .05), which
ranged from around 20% to 35%, was identified after 48 and
72 hours (Figure 5A). Although a 20% and significant de-
crease in b-catenin siRNA–transfected Hep3B cells was
observed at 48 hours (P < .05), a pronounced (> 50%) and
highly significant (P < .01) decrease was readily identifiable
at 72 hours (Figure 5B).
Because HepG2 cells harbor a b-catenin deletion render-
ing a more stable protein, we examined the efficacy of
employing serial CTNNB1 siRNA transfections in HepG2
cells, as detailed in the Materials and Methods section. An
additional transfection of CTNNB1 siRNA led to a dramatic
and extremely significant (P < .001) decrease in thymidine
incorporation after 24 hours (40%) and 48 hours (> 70%) in
HepG2 cells (Figure 5C). Thus, the above results demon-
strate a critical role of b-catenin in tumor cell proliferation.
Effect of -Catenin siRNA on the Soft Agar Growth
of Hepatoma Cells
Next, we examined the effect of b-catenin loss on the
growth of hepatoma cells in soft agar. Twenty-four hours
after the control or b-catenin siRNA transfection of HepG2
and Hep3B cells, these were cultured in soft agar for 14 and
21 days, respectively. A dramatic decrease in crystal violet–
stained colonies was evident in the b-catenin siRNA–trans-
fected HepG2 and Hep3B cells, as shown in representative
cultures (Figure 5D). This difference was statistically signif-
icant, with the numbers of colonies in the b-catenin siRNA–
transfected cells being around 30% of the control siRNA–
treated group (Figure 5E ).
Discussion
HCC is the commonest primary malignant tumor of the liver
that has been observed with increasing incidence due to an
increased prevalence of risk factors, including nonalcoholic
Figure 2. Changes in -catenin expression and localization after siRNA treatment in Hep3B and HepG2 cells by immunofluorescence. Left panel: Original mag-
nification, 600. Right panel: Original magnification, 1000. (A) Membranous and nuclear (arrowhead) -catenin is observed in Hep3B cells at 48 hours after
control siRNA transfection. (B) Decreased expression and nuclear localization of -catenin at 48 hours after -CTNNB1 siRNA transfection in Hep3B cells. (C)
Membranous and nuclear (arrowhead) -catenin is observed in HepG2 cells at 48 hours after control siRNA transfection. (D) Decreased expression and nuclear
localization of -catenin at 48 hours after -CTNNB1 siRNA transfection in HepG2 cells. A small subset of cells continued to show nuclear -catenin (arrowheads).
Figure 1. Effect of CTNNB1 siRNA on -catenin, GS, and cyclin D1 in human hepatoma cell lines (Hep3B and HepG2). All results for densitometry are presented
as the mean ± SEM of three experiments and normalized to their respective controls. (A) Western blot analysis shows a decrease in total -catenin, GS, and cyclin
D1 in HepG2 (left panel) and Hep3B (right panel) cells. A lower-molecular-weight (75 kDa) truncated form of -catenin (t-catenin) in HepG2 cells showed only a
modest decrease, especially at 48 and 72 hours. -Actin confirmed equal loading. (B) Densitometric analysis of HepG2 Western immunoblots revealed a significant
decrease in full-length -catenin protein (left panel) at 24 hours (P < .01), and in t-catenin (right panel) at 48 hours (P < .05), with a 40% additional loss at 72 hours
(P < .01). (C) Densitometric analysis of Hep3B immunoblots shows a significant decrease in -catenin protein at 24 hours, with a 50% additional decrease at
48 hours and a 70% additional decrease at 72 hours. (D) A significant decrease in cyclin D1 at 48 and 72 hours, and in GS at 72 hours (P < .05), after -catenin
siRNA transfection has been confirmed with densitometry in HepG2 cells. (E) A significant decrease in cyclin D1 and GS at 24, 48, and 72 hours (P < .01) after -
catenin siRNA transfection has been confirmed by densitometry in Hep3B cells.
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and alcoholic fatty liver disease and infections such as
hepatitis B and C [14,25]. In addition, the lack of optimal
treatment adds to the overall grim prognosis of the disease,
making it prudent to elucidate novel molecular mechanisms,
which in turn might reveal new therapeutic targets [25]. b-
Catenin, which is the chief oncogenic component of the
canonical Wnt pathway, has been identified to be active in
a significant subset of HCC, which, based on mechanisms,
ranges from 15% to 90% [12,17,26]. Furthermore, b-catenin
activation and cytoplasmic/nuclear localization have been
associated with increased proliferation and survival of
hepatocytes in normal physiology and tumor cell survival/
proliferation in HCC [2,20,21,26–28]. This implicates b-
catenin as an attractive therapeutic target in HCC. The
current study provides a proof of principle that b-catenin
inhibition is feasible, is of clinical relevance, and has func-
tional consequences in HCC cells, which show b-catenin
overexpression and/or activation.
We examined the effect of the inhibition of b-catenin by
siRNA in human HCC cell lines. In our current study, we used
two hepatoma cell lines that have appreciable b-catenin
expression but have distinct bases of b-catenin activation.
HepG2 cells have a heterozygous deletion of 348 nucleo-
tides in exon 3 of the -catenin gene, which encode a total of
116 amino acids from trytophan-25 to asparagine-141 [29].
Critical amino acids in this region have been shown to be
necessary for GSK3b or casein kinase–driven b-catenin
phosphorylation and eventual degradation [30–32]. Hep3B
cells, however, were derived from hepatitis B–infected liver
tumor, and although they do not contain any mutations or
deletions in the -catenin gene, these cells show high levels
of b-catenin protein [33,34]. One of the mechanisms of such
observation may be the presence of elevated levels of
inactive GSK3b (GSK3b Ser9–phosphorylated) in these
cells [34]. In our current study, we used these two cell lines
to examine the efficacy of b-catenin knockdown by siRNA
against CTNNB1 along with its functional consequences,
including effects on proliferation and survival.
A dramatic decrease in b-catenin expression, nuclear
localization, and activation was evident within 24 to 48 hours
in Hep3B cells, which exhibit elevated wild-type b-catenin. A
concomitant decrease in tumor cell proliferation, growth in
soft agar, and survival was also evident at the corresponding
times. The extent of the decrease in these biologic events
was fairly robust in these cells. A similar effect of CTNNB1
siRNA on the wild-type species of b-catenin in HepG2 cells
was evident within 24 to 48 hours. However, the effect of
siRNA on the truncated form, which is the predominant func-
tional form of b-catenin in HepG2 cells, was less dramatic
Figure 3. TOPflash reporter assay demonstrates a significant decrease in -
catenin transcriptional activity in Hep3B and HepG2 cells following -catenin
siRNA transfection for 48 hours (P < .01). Luciferase activity in FOPflash re-
mained unaffected, confirming a lack of nonspecific activation of the reporter
system. A vector containing Renilla luciferase was used as an internal control
for transfection efficiency, and the results are expressed as relative firefly/
Renilla luciferase activity. The results presented are the mean ± SEM for
three experiments.
Figure 4. Loss of -catenin affects Hep3B and HepG2 cell viability by MTT assay. The results represent the mean ± SEM of three experiments and are presented
as a bar graph after normalizing to the respective controls. (A) A significant decrease in the viability of HepG2 cells was observed after 48 and 72 hours of -catenin
siRNA transfection. (B) A significant decrease in the viability of Hep3B cells was observed at 24, 48, and 72 hours after -catenin siRNA transfection.
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and mainly evident after 48 hours. There was a modest but
significant decrease in tumor cell viability and proliferation
after 48 hours of CTNNB1 siRNA in this case, which might
be the consequence of the decrease in both wild-type and
truncated b-catenin species. In addition, the soft agar growth
of HepG2 was equally affected by siRNA against b-catenin
and was comparable to Hep3B cells, suggesting that sup-
pression of b-catenin transcription was equally efficacious in
long-term studies, irrespective of the mutational status of b-
catenin. Alternatively, tb-catenin was dramatically decreased
in HepG2 cells after two consecutive 24-hour transfections
with CTNNB1 siRNA, with a more robust decrease in tumor
cell proliferation. These findings clearly indicate the clinical
relevance of the transcriptional downregulation of b-catenin
in HCC.
Based on the above findings, there appears to be
an obvious merit of b-catenin suppression in b-catenin–
overexpressing liver tumors independent of any mutations
in CTNNB1. However, the caveat is that b-catenin sup-
pression would need to be prolonged in the event of muta-
tions in the -catenin gene itself, as the truncated protein
is stable over prolonged time. Nonetheless, sustained
Figure 5. Loss of -catenin compromises tumor cell proliferation by thymidine incorporation. The results represent the mean ± SEM of three experiments. (A) A
significant decrease in thymidine incorporation in HepG2 cells observed at 48 and 72 hours after -catenin siRNA transfection (P < .05). (B) A significant decrease
in thymidine incorporation in Hep3B cells observed after 48 and 72 hours of -catenin siRNA transfection (P < .01). (C) Bar graph shows a significant decrease in
thymidine incorporation (P < .001) by 40% and 70% in HepG2 cells at 24 and 48 hours, respectively, after two sequential siRNA transfections performed 24 hours
apart. Data presented were normalized to control siRNA for each time point and treatment. (D) A representative photograph shows a noteworthy decrease in the
numbers of soft agar colonies formed by HepG2 cells at 14 days, and by Hep3B cells at 21 days, after the initial 24-hour transfection with -catenin siRNA
compared to the controls. (E) Histogram shows a significant decrease in the number of colonies of both HepG2 (top) and Hep3B (bottom) in soft agar in the
-catenin siRNA– treated group compared to the respective controls at the same time (P < .01). The experiment was performed in triplicate, and average (±SD)
data were presented.
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b-catenin suppression in overexpressing tumors would have
promising biologic consequences on tumor cell viability and
proliferation.
Antisense modalities are being tested preclinically and clini-
cally, and are a part of a bigger ‘‘antigene’’ strategy for cancer
prevention and treatment [35]. Antisense therapies for treat-
ment in a clinical setup are still in the stage of infancy. The
current clinical trials are mainly aimed at chemosensitization
of the tumors and similar applications [36–38]. Although no
clinical studies are available, preclinical b-catenin suppres-
sion using antisense modalities has been shown to have
relevance in colorectal cancer cells and other tumor cells such
as melanoma and sarcoma [39–41]. It remains to be seen
whether successful b-catenin suppression through antisense
techniques, including classic antisense oligodeoxynucleotide
technology, antisense RNA technology, or additional means,
will have translational significance. Successful b-catenin sup-
pression in vivo has been achieved by phosphomorpholino
oligonucleotides during liver regeneration [42].
A yet another prospective way of b-catenin suppression
in the clinical setting might be the use of agents that inhibit
-catenin gene and protein expression, along with its activity.
PPAR-g agonists suppress b-catenin transcriptionally and
posttranslationally [43,44]. We have recently identified a role
for R-Etodolac in inhibiting b-catenin expression and activa-
tion as well [23]. Such agents would therefore have strong
clinical relevance in inhibiting b-catenin activity in liver can-
cers exhibiting b-catenin overexpression independent of mu-
tations in the -catenin gene.
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